Orion Portfolio Solutions LLC Has $5.10 Million Holdings in argenx SE (NASDAQ:ARGX)

Orion Portfolio Solutions LLC trimmed its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,298 shares of the company's stock after selling 502 shares during the period. Orion Portfolio Solutions LLC's holdings in argenx were worth $5,103,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of ARGX. Whipplewood Advisors LLC acquired a new stake in shares of argenx in the fourth quarter valued at $37,000. Global Retirement Partners LLC grew its holdings in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp increased its position in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock worth $46,000 after acquiring an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ARGX shares. Truist Financial reissued a "buy" rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Robert W. Baird lifted their target price on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a research note on Tuesday, March 4th. Wells Fargo & Company upped their price target on argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. JMP Securities raised their price target on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, William Blair reissued an "outperform" rating on shares of argenx in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, argenx presently has a consensus rating of "Moderate Buy" and an average price target of $687.00.

Remove Ads

argenx Stock Performance

ARGX stock traded up $9.14 during midday trading on Thursday, hitting $592.76. 349,687 shares of the company's stock were exchanged, compared to its average volume of 293,660. argenx SE has a one year low of $352.77 and a one year high of $678.21. The company has a market cap of $36.02 billion, a PE ratio of -673.59 and a beta of 0.60. The stock's fifty day moving average price is $624.55 and its 200-day moving average price is $602.58.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. On average, analysts expect that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.